Logo

Lynx Signs Service Agreement with NIMH to Study Gene Expression in the Brain

May 21, 2004

NEW YORK, May 21 (GenomeWeb News) - Lynx Therapeutics has signed a service contract with the National Institute of Mental Health to study gene expression in the brain, the company said today.

 

Under the agreement, with the NIMH's Genes, Cognition, and Psychosis program, Lynx will use its Massively Parallel Signature Sequencing technology to analyze gene expression in a region of the brain cortex that has been implicated in schizophrenia.

 

Lynx will receive payments for its services on samples provided by NIMH.

Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.